We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Johnson & Johnson (J&J) has submitted an sNDA for Risperdal Consta to expand the drug’s indication to include the maintenance treatment of bipolar I disorder in adults.